GlassScriptPhysician profile
Robert L Kirby
NPI 1104869544
$10,889.02
in general payments reported to CMS, 2019-2025
11 companies · $19.67 in 2025
The $19.67 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $5,150 · 2021: $3,065 · 2022: $1,279 · 2023: $299 · 2024: $544 · 2025: $19.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $337.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,816.66 | 2020-2022 | |
| Athenex Pharmaceutical Division, LLC | $3,850.00 | 2020 | |
| Daiichi Sankyo INC. | $1,222.88 | 2021-2024 | Enhertu |
| Puma Biotechnology, INC. | $506.72 | 2019-2023 | |
| Abbvie INC. | $150.36 | 2019-2025 | |
| Comsort, INC | $150.00 | 2019 | |
| Glaxosmithkline, LLC. | $100.00 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $54.90 | 2022-2023 | Imbruvica, Epkinly |
| Pfizer INC. | $14.70 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kirby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.